Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer (LARC)
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 30
- Registration Number
- NCT06459869
- Locations
- 🇬🇧
University College London NHS FT, London, United Kingdom
🇺🇸Ohio State University Comprehensive Cancer Center (OSU), Columbus, Ohio, United States
🇺🇸The University of Texas MD Anderson Cnacer Center, Houston, Texas, United States
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
- Conditions
- Epithelial TumorMetastatic Cancer
- Interventions
- Biological: NG-350A plus Pembrolizumab
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 198
- Registration Number
- NCT05165433
- Locations
- 🇺🇸
Providence Medical Foundation, Santa Monica, California, United States
🇺🇸UCLA, Santa Monica, California, United States
🇺🇸Moffitt-Advent Health Clinical Research Unit, Celebration, Florida, United States
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
- Conditions
- Metastatic CancerEpithelial Tumor
- Interventions
- Biological: NG-641 in combination with Nivolumab
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 30
- Registration Number
- NCT05043714
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸UCLA Department of Medicine, Santa Monica, California, United States
🇺🇸Moffitt-Advent Health Clinical Research Unit, Celebration, Florida, United States
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 36
- Registration Number
- NCT04830592
- Locations
- 🇬🇧
Cardiff & Vale University LHB, Cardiff, United Kingdom
🇬🇧The Clatterbridge Cancer Centre, Liverpool, United Kingdom
🇬🇧The Royal Marsden Hospital, London, United Kingdom
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 186
- Registration Number
- NCT04053283
- Locations
- 🇺🇸
University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA, Santa Barbara, California, United States
🇺🇸Moffitt-Advent Health Clinical Research Unit, Celebration, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Akamis Bio Initiates Phase 1b FORTRESS Trial of NG-350A for Locally Advanced Rectal Cancer
Akamis Bio has enrolled the first patient in its Phase 1b FORTRESS trial evaluating NG-350A in combination with standard chemoradiotherapy for locally advanced rectal cancer.